The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BNTX | +0.65% | +9.45% | +1.82% | +628% |
| S&P | +12.28% | +84.74% | +13.06% | +125% |
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.
The company's push deeper into a hot new technology, plus good news from a top collaborator, put the shine on its equity.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.77B | 29.8% |
| Gross Profit | $1.60B | 36.8% |
| Gross Margin | 90.24% | 4.6% |
| Market Cap | $23.71B | -16.0% |
| Market Cap / Employee | $3.50M | 0.0% |
| Employees | 6.8K | 10.4% |
| Net Income | -$33.54M | -115.4% |
| EBITDA | $888.56M | 97.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $11.86B | 10.4% |
| Accounts Receivable | $822.15M | -25.4% |
| Inventory | 265.2 | -21.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $225.60M | -2.0% |
| Short Term Debt | $62.75M | 50.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -2.53% | -0.5% |
| Return On Invested Capital | 27.28% | 5.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $811.14M | 204.2% |
| Operating Free Cash Flow | $854.59M | 224.2% |
| Metric | Q4 2023 | Q1 2024 | YoY Change | ||
|---|---|---|---|---|---|
| Price to Earnings | 25.39 | 179.40 | - | ||
| Price to Book | 1.28 | 1.09 | 1.25 | 1.09 | -18.23% |
| Price to Sales | 9.18 | 7.37 | 8.19 | 6.71 | -23.73% |
| Price to Tangible Book Value | 1.37 | 1.16 | 1.39 | 1.21 | -15.08% |
| Price to Free Cash Flow TTM | 4.64 | 3.84 | 6.39 | 19.65 | - |
| Enterprise Value to EBITDA | 27.31 | -13.87 | -17.57 | 8.00 | -66.28% |
| Free Cash Flow Yield | 21.5% | 26.1% | 15.6% | 5.1% | - |
| Return on Equity | -3.4% | -3.9% | -1.8% | -2.9% | 24.20% |
| Total Debt | $263.22M | $316.50M | $316.47M | $288.35M | 6.02% |
No podcast episodes available.
BNTX earnings call for the period ending December 31, 2024.
BNTX earnings call for the period ending September 30, 2024.
BNTX earnings call for the period ending June 30, 2024.
BNTX earnings call for the period ending March 31, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
